J&J Longs For Cypher Longevity, May Enjoy 15-Month Monopoly In Japan
This article was originally published in The Gray Sheet
Executive Summary
Cordis aims to expand the U.S. shelf life of its Cypher sirolimus-eluting stent after resolving manufacturing issues cited by FDA in an April 2004 warning letter
You may also be interested in...
Paris Course On Revascularization In Brief
Enter CoStar: Cobalt-chromium paclitaxel-eluting stent is associated with 2.9% target lesion revascularization (TLR) rate and 7.6% major adverse event rate in 12-month follow-up results of 145-patient EuroSTAR trial, presented by Keith Dawkins, MD, Southampton University Hospital, England. The firm recently launched the 1,700-patient, 90-site COSTAR-II pivotal study. The non-inferiority trial compares CoStar with Boston Scientific's Taxus (1"The Gray Sheet" May 16, 2005, p. 17)...
Paris Course On Revascularization In Brief
Enter CoStar: Cobalt-chromium paclitaxel-eluting stent is associated with 2.9% target lesion revascularization (TLR) rate and 7.6% major adverse event rate in 12-month follow-up results of 145-patient EuroSTAR trial, presented by Keith Dawkins, MD, Southampton University Hospital, England. The firm recently launched the 1,700-patient, 90-site COSTAR-II pivotal study. The non-inferiority trial compares CoStar with Boston Scientific's Taxus (1"The Gray Sheet" May 16, 2005, p. 17)...
Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC
Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus